As reported on by

As reported on by

A highly sensitive and specific, molecular point-of-care (POC), test-and-treat platform with sample to answer in about 30 minutes for the two most tested-for sexually transmitted infections (STIs), chlamydia (CT) and gonorrhea (NG).

Onsite testing using the binx io POC platform for the detection of CT/NG in women enables testing and treatment in a single visit. This new paradigm offers the potential to improve health outcomes by increasing treatment compliance and reducing onward transmission and the potential serious consequences of untreated infections.

Test-and-treat in a single visit.

The World Health Organization (WHO) estimates that each year, there are more than 376 million new sexually transmitted infections diagnosed globally — and two of the most common are chlamydia and gonorrhea. Typically, testing for these infections can take anywhere from days to weeks — and the number of undiagnosed infections is even greater. As a result, up to 40%[1] of positive patients in the US never return for treatment once they leave the physician's office.

The first-of-its-kind io platform from binx offers the potential to change the game. Testing for chlamydia and gonorrhea in women has never been so fast and accurate.

The buzz about the binx io revolution

Easy to use

Collect sample, load cartridge, press ‘start’

Fully automated

Results in about 30 minutes

Lab-quality testing

Performance comparable to central laboratory testing

The binx io platform is a small, benchtop instrument that processes a single-use, assay-specific cartridge containing all the necessary reagents for use on a single patient sample. The io is fully automated, so there are no additional user steps required once the cartridge is loaded into the instrument.

How it works

By combining ultra-rapid, polymerase chain reaction (PCR) amplification and the binx health proprietary and highly-sensitive electrochemical detection technology, the binx io test is able to return accurate results with performance on par with standard of care laboratory tests in about 30 minutes.

The binx io platform for women's health has been cleared by the FDA for use in point-of-care and clinical laboratory settings for the rapid and accurate detection of chlamydia and gonorrhea — in clinician- and patient-collected vaginal swab samples.

Want to know more?

Learn more about the binx io platform

*io®, the io Instrument®, and the io Cartridge® (together the “io Diagnostic System®”) are registered trademarks of binx health limited.